Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD

• Published in: Archivos de bronconeumología (English ed.) 2022-01, Vol.58 (1), p.69-81
• Main Authors: Miravitlles, Marc, Calle, Myriam, Molina, Jesús, Almagro, Pere, Gómez, José-Tomás, Trigueros, Juan Antonio, Cosío, Borja G, Casanova, Ciro, López-Campos, José Luis, Riesco, Juan Antonio, Simonet, Pere, Rigau, David, Soriano, Joan B, Ancochea, Julio, Soler-Cataluña, Juan José
• Format: Article
• Language: English
• ISSN: 1579-2129
• DOI: 10.1016/j.arbres.2021.03.005

The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since then have undergone a series of updates incorporating new evidence on the diagnosis and treatment of COPD. GesEPOC was drawn up in partnership with scientific societies involved in the treatment of COPD and the Spanish Patients' Forum. Their recommendations are based on an evaluation of the evidence using GRADE methodology, and a narrative description of the evidence in areas in which GRADE cannot be applied. In this article, we summarize the recommendations on the pharmacological treatment of stable COPD based on 9 PICO questions. COPD treatment is a 4-step process: 1) diagnosis, 2) determination of the risk level, 3) initial and subsequent inhaled therapy, and 4) identification and management of treatable traits. For the selection of inhaled therapy, high-risk patients are divided into 3 phenotypes: non-exacerbator, eosinophilic exacerbator, and non-eosinophilic exacerbator. Some treatable traits are general and should be investigated in all patients, such as smoking or inhalation technique, while others affect severe patients in particular, such as chronic hypoxemia and chronic bronchial infection. COPD treatment is based on long-acting bronchodilators with single agents or in combination, depending on the patient's risk level. Eosinophilic exacerbators must receive inhaled corticosteroids, while non-eosinophilic exacerbators require a more detailed evaluation to choose the best therapeutic option. The new GesEPOC also includes recommendations on the withdrawal of inhaled corticosteroids and on indications for alpha-1 antitrypsin treatment. GesEPOC offers a more individualized approach to COPD treatment tailored according to the clinical characteristics of patients and their level of complexity.